Patients with COVID-19 were divided into two groups according to the fraction of inspiration O2 (FiO2 < 45% or >45%) at the time of administration of IL-6R antibody treatment (sarilumab or tocilizumab). The gene discussed is IL6R; the disease is COVID-19.